Teva: We Believe In Biosimilars, But Pipeline And Timing Come First
‘There’ll Be Bumpiness But Opportunity Is Massive,’ Says New CEO Francis
Teva’s newly appointed CEO Richard Francis has underlined the company’s commitment to biosimilars, buoyed by his experience overseeing their progress at his former employer Sandoz.
